- Previous Close
35.57 - Open
35.76 - Bid 35.43 x 200
- Ask 35.84 x 200
- Day's Range
35.43 - 35.76 - 52 Week Range
18.61 - 40.60 - Volume
26,995 - Avg. Volume
409,487 - Market Cap (intraday)
2.024B - Beta (5Y Monthly) 0.73
- PE Ratio (TTM)
18.26 - EPS (TTM)
1.95 - Earnings Date Oct 29, 2024 - Nov 4, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
43.29
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
www.harmonybiosciences.comRecent News: HRMY
View More
Performance Overview: HRMY
Trailing total returns as of 10/3/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HRMY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HRMY
View MoreValuation Measures
Market Cap
2.02B
Enterprise Value
1.86B
Trailing P/E
18.24
Forward P/E
8.94
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.18
Price/Book (mrq)
3.75
Enterprise Value/Revenue
2.84
Enterprise Value/EBITDA
8.86
Financial Highlights
Profitability and Income Statement
Profit Margin
17.53%
Return on Assets (ttm)
13.75%
Return on Equity (ttm)
22.46%
Revenue (ttm)
656.11M
Net Income Avi to Common (ttm)
114.99M
Diluted EPS (ttm)
1.95
Balance Sheet and Cash Flow
Total Cash (mrq)
346.91M
Total Debt/Equity (mrq)
35.10%
Levered Free Cash Flow (ttm)
159.8M
Research Analysis: HRMY
View MoreCompany Insights: HRMY
HRMY does not have Company Insights
Research Reports: HRMY
View MoreRaising target price to $41.00
HARMONY BIOSCIENCES HOLDINGS has an Investment Rating of HOLD; a target price of $41.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of High; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetRaising target price to $41.00
HARMONY BIOSCIENCES HOLDINGS has an Investment Rating of HOLD; a target price of $41.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetRaising target price to $39.00
HARMONY BIOSCIENCES HOLDINGS has an Investment Rating of HOLD; a target price of $39.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetLowering target price to $37.00
HARMONY BIOSCIENCES HOLDINGS has an Investment Rating of HOLD; a target price of $37.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice Target